ILS Chief Scientific Officer Les Recio, PhD, DABT has been awarded a Small Business Innovative Research (SBIR) Grant from the NIEHS for his Phase I application, “Mutational profiling in human cells as an in vitro alternative to in vivo mutagenicity assessments.” The focus of this SBIR is to develop a novel approach using duplex sequencing in human cells as an analytical assessment of mutagenicity by Next Generation Sequencing to quantify these very rare events (1 in 100,000 to 1,000,000) in an in vitro system. The results from this initial study will be used in a future Phase II application that will be designed to further develop and implement the assay as a commercially available service offered by ILS.
